National Bank of Canada’s Innate Pharma IPHA Stock Holding History

National Bank of Canada’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-450	Closed	-$828	–	2988
2024 Q4	$828	Buy	+450	New	+$845	﹤0.01%	2662

Other funds holding IPHA

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

National Bank of Canada's IPHA Position: Q1 2025 in Review

National Bank of Canada sold out of Innate Pharma (IPHA) in Q1 2025, closing a stake of 450 shares — an estimated $828 sold.

National Bank of Canada first reported a position in IPHA in Q4 2024 and held it in 1 quarter. The position peaked at $828 in Q4 2024. 10 funds tracked by Wall St. Rank hold IPHA as of Q1 2025.

National Bank of Canada reported no remaining Innate Pharma position as of Q1 2025 after selling out during the quarter.
National Bank of Canada sold 450 Innate Pharma shares in Q1 2025, an estimated $828.
National Bank of Canada first reported a position in Innate Pharma in Q4 2024 and held it in 1 quarter.
National Bank of Canada's Innate Pharma position peaked at $828 in Q4 2024.
10 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2025.

Based on National Bank of Canada's 13F filing for Q1 2025, filed 12 May 2025.